Across TCGA pan-cancer cohorts, PCYT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCYT2 data layer compared with 18 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PCYT2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PCYT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where PCYT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	0.959	0.588	.007	46	view →
PDAC	DFS	Median	All	0.491	0.316	.002	21	view →
GBM	DFS	Median	All	0.260	0.480	.010	8	view →
LUAD	OS	Tertile	All	0.891	0.400	.002	8	view →
LSCC	DFS	Tertile	II,III,IV	0.920	1.000	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PCYT2 tumor-vs-normal RNA expression · all PCYT2 data types